Investigators sought to summarize evidence about the benefits and harms of hydroxychloroquine and chloroquine as treatments or prophylaxis of COVID-19.
Early links between heart disease and diabetes and coronavirus severity caused some to fear that the 2 classes of medication might worsen outcomes during the pandemic. A systematic review finds little evidence to back those fears.
An assessment of severe coronavirus patients administered either five-day or 10-day remdesivir treatment shows benefit is fairly similar, regardless of duration.
